Scarica l'app Stockscreener
119.35
0.29%
0.35
Precedente Chiudi:
$119.00
Aprire:
$119.52
Volume 24 ore:
665.43K
Relative Volume:
0.87
Capitalizzazione di mercato:
$9.82B
Reddito:
$51.48M
Utile/perdita netta:
$-315.00M
Rapporto P/E:
-33.42
EPS:
-3.5708
Flusso di cassa netto:
$-244.00M
1 W Prestazione:
+5.14%
1M Prestazione:
+52.56%
6M Prestazione:
+59.62%
1 anno Prestazione:
+163.99%
Intervallo 1D:
$114.00
$120.60
Intervallo di 1 settimana:
$111.21
$120.90
Portata 52W:
$36.65
$130.05
Kymera Therapeutics Inc Stock (KYMR) Company Profile
Nome
Kymera Therapeutics Inc
Settore
Industria
Telefono
857-285-5314
Indirizzo
500 NORTH BEACON STREET, 4TH FLOOR, WATERTOWN
Compare KYMR vs VRTX, REGN, ARGX, ALNY, RVMD
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
KYMR
Kymera Therapeutics Inc
|
119.35 | 9.82B | 51.48M | -315.00M | -244.00M | -3.5708 |
VRTX
Vertex Pharmaceuticals Inc
|
485.39 | 123.19B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
664.52 | 69.67B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
877.62 | 54.58B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
298.76 | 39.89B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
186.88 | 39.73B | 742.00K | -1.37B | -1.07B | -7.0731 |
Kymera Therapeutics Inc Stock (KYMR) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-03-16 | Ripresa | Jefferies | Buy |
| 2026-01-28 | Ripresa | Barclays | Overweight |
| 2026-01-06 | Downgrade | Wolfe Research | Outperform → Peer Perform |
| 2025-11-03 | Ripresa | Guggenheim | Buy |
| 2025-10-24 | Reiterato | B. Riley Securities | Buy |
| 2025-10-21 | Iniziato | Mizuho | Outperform |
| 2025-09-18 | Reiterato | H.C. Wainwright | Buy |
| 2025-09-17 | Iniziato | Barclays | Overweight |
| 2025-09-16 | Iniziato | RBC Capital Mkts | Outperform |
| 2025-07-30 | Ripresa | B. Riley Securities | Buy |
| 2025-07-03 | Ripresa | Morgan Stanley | Overweight |
| 2025-06-03 | Aggiornamento | B. Riley Securities | Neutral → Buy |
| 2025-06-03 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2025-06-02 | Aggiornamento | BofA Securities | Neutral → Buy |
| 2025-05-20 | Ripresa | Stifel | Buy |
| 2025-03-13 | Iniziato | Citigroup | Buy |
| 2024-12-10 | Iniziato | BTIG Research | Buy |
| 2024-12-06 | Iniziato | BMO Capital Markets | Market Perform |
| 2024-12-02 | Aggiornamento | Wells Fargo | Equal Weight → Overweight |
| 2024-11-18 | Iniziato | Stephens | Overweight |
| 2024-09-09 | Ripresa | Leerink Partners | Outperform |
| 2024-08-26 | Aggiornamento | Wolfe Research | Peer Perform → Outperform |
| 2024-04-22 | Iniziato | Oppenheimer | Outperform |
| 2024-02-15 | Iniziato | Wolfe Research | Peer Perform |
| 2024-01-04 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2024-01-03 | Downgrade | BofA Securities | Buy → Neutral |
| 2023-12-19 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| 2023-06-30 | Iniziato | Truist | Buy |
| 2023-05-05 | Aggiornamento | Raymond James | Mkt Perform → Outperform |
| 2022-12-06 | Downgrade | Credit Suisse | Outperform → Neutral |
| 2022-11-08 | Iniziato | Raymond James | Mkt Perform |
| 2022-08-15 | Iniziato | Jefferies | Buy |
| 2022-08-03 | Iniziato | Goldman | Buy |
| 2022-07-20 | Iniziato | SVB Leerink | Mkt Perform |
| 2022-04-28 | Iniziato | Credit Suisse | Outperform |
| 2022-03-10 | Iniziato | JP Morgan | Neutral |
| 2022-02-10 | Iniziato | Wells Fargo | Overweight |
| 2021-09-30 | Iniziato | B. Riley Securities | Neutral |
| 2021-09-30 | Iniziato | Stifel | Buy |
| 2021-09-10 | Downgrade | BofA Securities | Buy → Neutral |
| 2021-05-21 | Iniziato | UBS | Buy |
| 2021-04-14 | Iniziato | Berenberg | Buy |
| 2020-12-04 | Iniziato | H.C. Wainwright | Buy |
| 2020-09-15 | Iniziato | BofA Securities | Neutral |
| 2020-09-15 | Iniziato | Cowen | Outperform |
| 2020-09-15 | Iniziato | Guggenheim | Buy |
| 2020-09-15 | Iniziato | Morgan Stanley | Equal-Weight |
Mostra tutto
Kymera Therapeutics Inc Borsa (KYMR) Ultime notizie
Strength seen in Kymera Therapeutics (KYMR): Can its 16.6% jump turn into more strength? - MSN
Is Kymera (KYMR) the Best Performing American Stock in June 2026? - Insider Monkey
Kymera jumps 17% on early enrollment completion in skin disease study - MSN
Hedge Fund and Insider Trading News: Bill Ackman, Ken Griffin, Warren Buffett, Ray Dalio, Scion Asset Management, Brevan Howard, Kymera Therapeutics Inc (KYMR), Sony Group Corp (SONY), and More - Insider Monkey
(KYMR) Price Dynamics and Execution-Aware Positioning - Stock Traders Daily
Kymera Therapeutics Insider Sold Shares Worth $5,950,000, According to a Recent SEC Filing - marketscreener.com
Kymera Therapeutics(KYMR.US) Officer Sells US$5.95 Million in Common Stock - Moomoo
Form 4 Kymera Therapeutics Inc For: 7 July By Investing.com - Investing.com Nigeria
Kymera Therapeutics CEO Mainolfi sells $5.95m in stock By Investing.com - Investing.com India
Kymera Therapeutics CEO Mainolfi sells $5.95m in stock - Investing.com
Form 144 Kymera Therapeutics For: 7 July By Investing.com - Investing.com Nigeria
Kymera Therapeutics, Inc. Announces Appointment of Elizabeth Laws as Senior Vice President - marketscreener.com
Kymera hires ex-Sanofi executive to lead KT-621 development - Investing.com
Kymera hires ex-Sanofi executive to lead KT-621 development By Investing.com - Investing.com South Africa
Kymera Therapeutics Appoints Elizabeth Laws, Ph.D., as Senior Vice President, Global Program Team Leader for KT-621, First-in-Class, Oral STAT6 Degrader - The Manila Times
Kymera Therapeutics Insider Sold Shares Worth $8,864,829, According to a Recent SEC Filing - Moomoo
KYMRKymera Therapeutics Inc Options - Finviz
Kymera Therapeutics: Why It May Be Time To Jump On The Bandwagon (Upgrade) (NASDAQ:KYMR) - Seeking Alpha
Kymera: Building Toward A Defining 2H26 Moment (NASDAQ:KYMR) - Seeking Alpha
Kymera Therapeutics (KYMR) Stock Gets Fair Value Bump After KT 621 Timeline Shift - Yahoo Finance
Kymera Therapeutics(KYMR.US) Officer Sells US$9.22 Million in Common Stock - Moomoo
How Accelerated KT-621 Trial, Index Additions, and New Chair Will Impact Kymera Therapeutics (KYMR) Investors - Yahoo Finance
Insider Sell: Noah Goodman Sells Shares of Kymera Therapeutics I - GuruFocus
Kymera Therapeutics director Bruce Booth sells $8.28m in shares By Investing.com - Investing.com Australia
Kymera Therapeutics director Bruce Booth sells $8.28m in shares - Investing.com
Form 4 Kymera Therapeutics Inc For: 2 July By Investing.com - Investing.com Canada
Form 144 Kymera Therapeutics For: 2 July By Investing.com - Investing.com Canada
Kymera Therapeutics (KYMR) Is Up 16.7% After KT-621 Trial Acceleration And Index Additions Has The Bull Case Changed? - Sahm
KYMR Stock Soars 51% YTD on Progress of Atopic Dermatitis Drug - Yahoo Finance
KYMR Stock Clocks Best Day In Over 6 Months On Advancing Eczema Trial Timeline - Stocktwits
Kymera Therapeutics director sells $56.5m in shares - Investing.com UK
Form 4 Kymera Therapeutics Inc For: 30 June By Investing.com - Investing.com Nigeria
Kymera Therapeutics director sells $56.5m in shares By Investing.com - Investing.com South Africa
Kymera Therapeutics director Booth sells $3.42 million in KYMR shares - Investing.com
Kymera Therapeutics director Booth sells $3.42 million in KYMR shares By Investing.com - Investing.com India
Kymera Therapeutics(KYMR.US) Director Sells US$59.88 Million in Common Stock - Moomoo
BofA Securities Initiates Kymera Therapeutics(KYMR.US) With Buy Rating, Announces Target Price $125 - Moomoo
BofA Securities Maintains Kymera Therapeutics(KYMR.US) With Buy Rating, Raises Target Price to $125 - Moomoo
KYMR Maintained by B of A Securities -- Price Target Raised to $125 - GuruFocus
KYMR Maintained by B. Riley Securities -- Price Target Raised to $155 - GuruFocus
Form 144 KYMERA THERAPEUTICS For: 29 June By Investing.com - Investing.com Nigeria
KYMR Maintained by Truist Securities -- Price Target Raised to $136 - GuruFocus
B. Riley Securities Maintains Kymera Therapeutics(KYMR.US) With Buy Rating, Raises Target Price to $155 - Moomoo
Kymera Therapeutics, Inc.(NasdaqGM: KYMR) added to Russell 2000 Value Benchmark - marketscreener.com
Truist raises Kymera Therapeutics price target on AD timeline By Investing.com - Investing.com Canada
B. Riley Adjusts Kymera Therapeutics Price Target to $155 From $117, Maintains Buy Rating - marketscreener.com
Kymera Therapeutics Inc Azioni (KYMR) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
2.64%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):